经皮穴位电刺激治疗ICU重度胃肠功能损伤的优劣:前瞻性随机对照试验
该前瞻性单中心随机对照试验纳入133例ICU重度胃肠功能损伤(AGI 2~3级)患者,随机分为TEAS组(68例)和对照组(65例),两组均接受常规治疗和肠内营养,TEAS组另予内关、足三里穴位电刺激,每次30分钟、每日2次、共7天。结果显示TEAS组I-FABP和D-乳酸下降幅度均大于对照组,肠内营养总时间、总热量及70%目标热量达标率更高,腹胀发生率更低,但腹泻发生率更高。两组瓜氨酸水平、AGI降级率、喂养中断率及28天累积生存率无显著差异。结论认为TEAS的优势在于逆转肠细胞坏死、促进肠屏障重建和改善胃肠耐受,局限在于不促进肠细胞吸收合成功能恢复、可能因耐受改善导致营养液过量、且不改善28天生存率。
要点
- TEAS组校正后I-FABP的LS均值差为-0.23 μg/L(95%CI -0.45~-0.01,P=0.041),降幅大于对照组,且与AGI分级存在显著交互(P=0.004)。
- TEAS组校正后D-乳酸的LS均值差为-0.08 mmol/L(95%CI -0.11~-0.05,P<0.001),降幅大于对照组,与AGI分级交互显著(P=0.005)。
- TEAS组肠内营养总时间72±31小时 vs 对照组60±28小时,总热量11 469.23±7 237.34 kJ vs 6 638.76±5 098.37 kJ,70%目标热量达标率52.9% vs 32.3%(均P<0.05)。
- TEAS组肠内营养后腹胀发生率23.5% vs 对照组43.1%,腹泻发生率22.1% vs 对照组7.7%(均P<0.05)。
- 两组28天累积生存率无显著差异(Log-Rank P=0.501,HR=0.81,95%CI 0.43~1.51),瓜氨酸水平无显著变化(LS均值差-0.17 μmol/L,95%CI -1.87~1.53,P=0.845)。
适用人群与场景
- 年龄>18岁、急性胃肠功能损伤(AGI)2~3级、血流动力学稳定的ICU患者。
诊断标准与关键阈值
- 急性胃肠功能损伤(AGI)分级2~3级。
处置流程与药物剂量
- 两组均接受常规治疗和肠内营养(EN)。
- TEAS组在常规治疗和EN基础上,于内关和足三里穴位行经皮穴位电刺激,每次30分钟,每日2次,共7天。
研究设计与关键结果
- 研究类型为前瞻性单中心随机对照试验,最终纳入133例患者,TEAS组68例、对照组65例,两组基线特征可比。
- I-FABP:两组治疗后均较治疗前下降,TEAS组降幅更明显;校正后I-FABP的LS均值差为-0.23 μg/L(95%CI -0.45~-0.01,P=0.041),与AGI分级交互显著(P=0.004)。
- D-乳酸:两组治疗后均较治疗前下降,TEAS组降幅更显著;校正后D-乳酸的LS均值差为-0.08 mmol/L(95%CI -0.11~-0.05,P<0.001),与AGI分级交互显著(P=0.005)。
- 瓜氨酸:两组治疗前后均无显著变化,校正后LS均值差为-0.17 μmol/L(95%CI -1.87~1.53,P=0.845),与AGI分级无显著交互(P=0.913)。
- EN耐受指标:TEAS组总EN时间72±31小时 vs 对照组60±28小时,总EN热量11 469.23±7 237.34 kJ vs 6 638.76±5 098.37 kJ,70%目标热量达标率52.9% vs 32.3%(均P<0.05);TEAS组EN后腹胀发生率23.5% vs 对照组43.1%(P<0.05),腹泻发生率22.1% vs 对照组7.7%(P<0.05)。
- AGI降级率、EN后呕吐/胃潴留率、喂养中断发生率及28天生存率两组无显著差异,且这些指标与AGI分级无显著交互。
- Kaplan-Meier生存分析显示两组28天累积生存率无显著差异(Log-Rank检验P=0.501,HR=0.81,95%CI 0.43~1.51),与AGI分级无显著交互(P=0.702)。
证据类型、等级与局限
- 证据类型:前瞻性单中心随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为TEAS的优势在于能逆转肠细胞坏死、促进肠屏障功能重建,并显著改善胃肠耐受、增加EN时间和总热量。
- 作者认为TEAS的局限在于不促进目标患者的肠细胞吸收和合成功能恢复,且可能因胃肠耐受改善导致营养液过量,同时似乎不改善目标患者的28天累积生存率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the advantages and limitations of transcutaneous electrical acupoint stimulation (TEAS) in the treatment of patients with severe gastrointestinal function injury in intensive care unit (ICU) by analyzing dynamic changes of intestinal fatty acid binding protein (I-FABP), D-lactic acid and citrulline.
METHODS: A prospective single-center randomized controlled trial was conducted. Patients with severe gastrointestinal function injury admitted to the ICU from February 2021 to January 2024 were enrolled [age > 18 years old, acute gastrointestinal injury (AGI) grade 2 to 3, stable hemodynamics]. Patients with different AGI grades were randomly assigned in a 1:1 ratio to the TEAS group and the control group using simple randomization. Both groups received conventional treatment and enteral nutrition (EN). In addition, the TEAS group underwent TEAS at the Neiguan and Zusanli points for 30 minutes per session, twice daily for 7 days. Baseline data, including age, gender, underlying diseases, and primary diagnoses, were recorded. Three intestinal biomarkers, such as I-FABP, D-lactic acid, and citrulline were measured before and after 7 days of treatment. EN tolerance indicators and 28 days survival status were documented. The differences in various indicators were compared between the two groups, subgroup analyses were conducted based on AGI grading, and interaction between AGI grade and TEAS were analyzed. The 28-day Kaplan-Meier survival curves were generated for both groups.
RESULTS: Finally, 133 patients were included, with 68 in the TEAS group and 65 in the control group. Baseline characteristics were comparable between the two groups. A comparison of the dynamic changes in intestinal biomarkers revealed that the I-FABP level in both groups decreased after treatment compared to pre-treatment, with a more pronounced reduction in the TEAS group. The least square mean difference (LS Mean difference) for the corrected I-FABP level between the two groups during the observation period was -0.23 μg/L [95% confidence interval (95%CI) was -0.45 to -0.01], which was statistically significant (P = 0.041). Additionally, a significant interaction with AGI was observed (P = 0.004). Post-treatment, D-lactic acid level decreased in both groups compared to pre-treatment, with a more significant reduction in the TEAS group. The LS Mean difference for the corrected D-lactic acid level was -0.08 mmol/L (95%CI was -0.11 to -0.05), which was statistically significant (P < 0.001), and the interaction with AGI was also significant (P = 0.005). There was no significant change in citrulline levels between the two groups before and after treatment. The LS Mean difference for the corrected citrulline level was -0.17 μmol/L (95%CI was -1.87 to 1.53), which was not statistically significant (P = 0.845), and no significant interaction with AGI was observed (P = 0.913). Comparison of EN tolerance parameters between the two groups revealed that the TEAS group had a longer total EN time (hours: 72±31 vs. 60±28) and higher total EN calories (kJ: 11 469.23±7 237.34 vs. 6 638.76±5 098.37), as well as a higher 70% target caloric attainment rate (52.9% vs. 32.3%) compared to the control group (all P < 0.05). The incidence of abdominal distension after EN was lower in the TEAS group than that in the control group (23.5% vs. 43.1%, P < 0.05), while the incidence of diarrhea after EN was higher in the TEAS group (22.1% vs. 7.7%, P < 0.05). There were no significantly differences in AGI grade reduction rate, post-EN vomiting/gastric retention rate, incidence of feeding interruption, and 28-day survival rate between the two groups. Furthermore, there were no significantly interaction between these observation measures and AGI. Kaplan-Meier survival analysis showed that there was no significantly difference in 28-day cumulative survival rate between the TEAS group and the control group [Log-Rank test: P = 0.501, hazard ratio (HR) = 0.81, 95%CI was 0.43-1.51), and there was no significantly interaction with AGI (P = 0.702).
CONCLUSIONS: The advantage of TEAS in the treatment of ICU patients with severe gastrointestinal function injury lies in its ability to reverse intestinal cell necrosis and promote the reconstruction of intestinal barrier function. Additionally, gastrointestinal tolerance is significantly improved, and both the duration and total calories of EN are increased. However, the limitation of TEAS therapy is that it does not promote the recovery of intestinal cell absorption and synthesis function in the target patients. Moreover, it may lead to nutrient solution overload due to improved gastrointestinal tolerance. Furthermore, TEAS does not appear to improve 28-day cumulative survival rate in the target patients.
参考来源
- Xu L, Chen Y, Lu J, et al. [Advantages and limitations of transcutaneous electrical acupoint stimulation in the treatment of patients with severe gastrointestinal function injury in intensive care unit: a prospective randomized controlled trial]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 40819946. doi:10.3760/cma.j.cn121430-20240512-00427
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。